United Therapeutics Corporation

UTHR
UTHR logo

Statistics

gray dotBusiness Model Rating
$139.51Share Price
$6.2 BMarket Cap
21.1%EBIT / EV
13.7%FCF / EV
103.0%ROIC
67.3%Cash ROIC
12.7%3yr Avg Revenue Growth
2.08Current Ratio
star logo

Business Model Diligence

We have a Business Model Diligence rating and review for this stock, but you must have a MagicDiligence Membership to view it. If you are already a member, you need to log in first.

Statistical Diligence

gray wandCurrent member of one or more spells! Log in to see which ones.
check mark The EBIT / Enterprise Value of 21.1% ranks as Very High.
check mark The Free Cash Flow / Enterprise Value of 13.7% ranks as Very High.
check mark The Return on Invested Capital Value of 103.0% ranks as Very High.
check mark The Cash Return on Capital Value of 67.3% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 12.7% ranks as Above Average.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 2.08.

Company Description

United Therapeutics Corp. engages in the development and commercialization of innovative products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension, high-risk neuroblastoma. It is also involved in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 29.36%
purple wand Deep Value 24.71%
orange wand Quality Growth 44.22%
green wand Green Team 6.14%
red dot Red Rating 5.76%
yellow dot Yellow Rating 14.17%
green dot Green Rating 14.95%
New Spell Stocks
purple wand New Stocks Added!
orange wand New Stocks Added!